Discovery of SU086 as an inhibitor of glycolysis and a potential treatment strategy for advanced prostate cancer

February 15, 2022

The Stoyanova Lab discovers that SU086, an HSP90 inhibitor, inhibits glycolysis and exhibits therapeutic potential in advanced prostate cancer. Congratulations Meghan and team!

https://pubmed.ncbi.nlm.nih.gov/35243415/

February 15, 2022

PreviousCaden James Denning, undergraduate at Stanford University, joins the Stoyanova Lab
NextDiscussion of the emergence and therapeutic potential for neuroendocrine prostate cancer

Related Posts ...

Exciting news: Dr. Hyeonji Hwang, a postdoctoral fellow at Dr. Stoyanova’s Lab in UCLA, awarded the Prostate Cancer Research Program Early Investigator Research Award by the US Department of Defense (DOD) for the project titled “Targeting Trop2-Mediated Ferroptosis as a New Therapy for Advanced Prostate Cancer”

Exciting News: Dr. Tanya Stoyanova receives 2025 Neuroendocrine Tumor Research Foundation Pilot Award